Dec 3, 2012 by Max Macaluso and Brenton FlynnRenewed Hope for Alzheimer's Patients - and Investors?Will Merck's experimental drug go the distance?
Nov 29, 2012 by Max Macaluso and Brenton FlynnIs There Hope for Pfizer Post-Lipitor?Now that the best selling drug in pharmaceutical history has gone off patent, what's next for Pfizer?
Nov 29, 2012 by Max Macaluso and Brenton FlynnIs This Dividend Pharma Stock Going Against the Grain?Merck pushes on despite Singulair's patent expiration.
Nov 29, 2012 by Max Macaluso and Dave WilliamsonAmarin Investors Still Treading WaterWhen Amarin will know about NCE status for its drug Vascepa, and what it means for the company's future.
Nov 29, 2012 by Max Macaluso and Dave Williamson1 Deal Arena Investors Might Have MissedBut don't celebrate just yet.
Nov 29, 2012 by Max Macaluso and Brenton FlynnBig Changes Up Ahead for Abbott InvestorsThe Abbott of 2013 is going to look very different from the Abbott of 2012.
Nov 27, 2012 by Max Macaluso and Brenton FlynnWill This New Orphan Drug Go the Distance?Merck and partner Endocyte may be one step closer to approval in Europe for their new orphan drug.
Nov 27, 2012 by Max Macaluso and Brenton FlynnWill These Patents Be the Key to Amarin's Success?Will these patents help Amarin's drug Vascepa succeed?
Nov 27, 2012 by Max Macaluso and Brenton FlynnWill This Strategy Spark a VIVUS Revival?VIVUS' powerful new obesity drug isn't selling. Will the company's new strategy have any effect?
Nov 26, 2012 by Max Macaluso and Brenton FlynnWill This Fish Oil Deal Affect Amarin? BASF's new foray into pharmaceuticals means it will soon produce Amarin's biggest competitor.
Nov 26, 2012 by Max Macaluso and Brenton FlynnWill VIVUS' Strategy Jump-Start Sales?Can VIVUS' marketing shift get its new obesity drug off the ground?
Nov 23, 2012 by Max Macaluso and Dave WilliamsonA Must-See Look at Amarin's Best- and Worst-Case ScenariosWhile investors wait on Vascepa's NCE status, we look at the best - and worst - things that could happen.
Nov 21, 2012 by Max Macaluso and Dave WilliamsonWhy Do Amarin Shareholders Want a Buyout?Without a buyout offer, can Amarin really market its new drug Vascepa on its own?
Nov 20, 2012 by Max Macaluso and Dave WilliamsonIs This the Key for Amarin?Amarin is looking at new ways to shore up its defenses against generic competition.
Nov 20, 2012 by Max Macaluso and Dave WilliamsonBiotech Banter: Are Scientists Better CEOs?Do you need an M.D. or Ph.D to be a CEO?
Nov 19, 2012 by Max Macaluso and Dave WilliamsonBiotech Banter: Is This Pharma Giant a Keeper?Reasons to buy and sell Merck.
Nov 16, 2012 by Max Macaluso and Dave WilliamsonNo News Equals Bad News for Amarin InvestorsThe waiting continues for Vascepa's NCE status.
Nov 16, 2012 by Max Macaluso and Dave WilliamsonShould VIVUS Look for a Buyer?Is a buyout a good strategy?
Nov 15, 2012 by Max Macaluso and Dave WilliamsonA New Player in the Amarin Buyout Saga?An unexpected new drugmaker has stepped into the story.
